160 related articles for article (PubMed ID: 36123073)
1. Study protocol for a randomised, double-blind, placebo-controlled crossover trial assessing the impact of the SGLT2 inhibitor empagliflozin on postprandial hypoglycaemia after gastric bypass.
Ferreira A; Emara AFA; Herzig D; Melmer A; Vogt AP; Nakas CT; Facchinetti A; Dalla Man C; Bally L
BMJ Open; 2022 Sep; 12(9):e060668. PubMed ID: 36123073
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass.
Ferreira A; Schönenberger KA; Potoczna N; Vogt A; Gerber PA; Zehetner J; Giachino D; Nett P; Gawinecka J; Cossu L; Fuster DG; Dalla Man C; Facchinetti A; Melmer A; Nakas CT; Hepprich M; Donath MY; Herzig D; Bally L
Diabetes Technol Ther; 2023 Jul; 25(7):467-475. PubMed ID: 37093196
[No Abstract] [Full Text] [Related]
3. Canagliflozin or acarbose versus placebo to ameliorate post-bariatric hypoglycaemia - The HypoBar I randomized clinical trial protocol.
Lobato CB; Winding CT; Bojsen-Møller KN; Martinussen C; Veedfald S; Holst JJ; Madsbad S; Jørgensen NB; Dirksen C
Diabet Med; 2024 Jun; 41(6):e15320. PubMed ID: 38551152
[TBL] [Abstract][Full Text] [Related]
4. Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial.
Schietzel S; Bally L; Cereghetti G; Faller N; Moor MB; Vogt B; Rintelen F; Trelle S; Fuster D
BMJ Open; 2022 Mar; 12(3):e059073. PubMed ID: 35288397
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes.
Yabe D; Shiki K; Suzaki K; Meinicke T; Kotobuki Y; Nishida K; Clark D; Yasui A; Seino Y
BMJ Open; 2021 Apr; 11(4):e045844. PubMed ID: 33827843
[TBL] [Abstract][Full Text] [Related]
6. Postprandial Hypoglycemia in Patients after Gastric Bypass Surgery Is Mediated by Glucose-Induced IL-1β.
Hepprich M; Wiedemann SJ; Schelker BL; Trinh B; Stärkle A; Geigges M; Löliger J; Böni-Schnetzler M; Rudofsky G; Donath MY
Cell Metab; 2020 Apr; 31(4):699-709.e5. PubMed ID: 32197070
[TBL] [Abstract][Full Text] [Related]
7. Nutritional strategies for correcting low glucose values in patients with postbariatric hypoglycaemia: A randomized controlled three-arm crossover trial.
Schönenberger KA; Ferreira A; Stebler C; Prendin F; Gawinecka J; Nakas CT; Mühlebach S; Stanga Z; Facchinetti A; Herzig D; Bally L
Diabetes Obes Metab; 2023 Oct; 25(10):2853-2861. PubMed ID: 37336721
[TBL] [Abstract][Full Text] [Related]
8. Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
Nielsen CK; Øhrstrøm CC; Kielgast UL; Hansen DL; Hartmann B; Holst JJ; Lund A; Vilsbøll T; Knop FK
Diabetes Care; 2022 Jun; 45(6):1476-1481. PubMed ID: 35320361
[TBL] [Abstract][Full Text] [Related]
9. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
Mordi NA; Mordi IR; Singh JS; Baig F; Choy AM; McCrimmon RJ; Struthers AD; Lang CC
BMJ Open; 2017 Oct; 7(10):e018097. PubMed ID: 29042392
[TBL] [Abstract][Full Text] [Related]
10. Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide.
Øhrstrøm CC; Worm D; Højager A; Andersen D; Holst JJ; Kielgast UL; Hansen DL
Diabetes Obes Metab; 2019 Sep; 21(9):2142-2151. PubMed ID: 31144430
[TBL] [Abstract][Full Text] [Related]
11. Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial.
Raven LM; Muir CA; Kessler Iglesias C; Bart NK; Muthiah K; Kotlyar E; Macdonald P; Hayward CS; Jabbour A; Greenfield JR
BMJ Open; 2023 Mar; 13(3):e069641. PubMed ID: 36990488
[TBL] [Abstract][Full Text] [Related]
12. Study rationale and design of the EANITIATE study (EmpAgliflozin compared to NPH Insulin for sTeroId diAbeTEs) - a randomized, controlled, multicenter trial of safety and efficacy of treatment with empagliflozin compared with NPH-insulin in patients with newly onset diabetes following initiation of glucocorticoid treatment.
Klarskov CK; Holm Schultz H; Persson F; Møller Christensen T; Almdal TP; Snorgaard O; Bagge Hansen K; Pedersen-Bjergaard U; Lommer Kristensen P
BMC Endocr Disord; 2020 Jun; 20(1):86. PubMed ID: 32539810
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
14. Investigating the roles of hyperglycaemia, hyperinsulinaemia and elevated free fatty acids in cardiac function in patients with type 2 diabetes via treatment with insulin compared with empagliflozin: protocol for the HyperCarD2 randomised, crossover trial.
Thirumathyam R; Richter EA; Goetze JP; Fenger M; Van Hall G; Dixen U; Holst JJ; Madsbad S; Vejlstrup N; Madsen PL; Jørgensen NB
BMJ Open; 2022 Aug; 12(8):e054100. PubMed ID: 35953245
[TBL] [Abstract][Full Text] [Related]
15. Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia.
Craig CM; Liu LF; Deacon CF; Holst JJ; McLaughlin TL
Diabetologia; 2017 Mar; 60(3):531-540. PubMed ID: 27975209
[TBL] [Abstract][Full Text] [Related]
16. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
Santos-Gallego CG; Garcia-Ropero A; Mancini D; Pinney SP; Contreras JP; Fergus I; Abascal V; Moreno P; Atallah-Lajam F; Tamler R; Lala A; Sanz J; Fuster V; Badimon JJ
Cardiovasc Drugs Ther; 2019 Feb; 33(1):87-95. PubMed ID: 30675708
[TBL] [Abstract][Full Text] [Related]
17. Effects of sodium-glucose co-transporter 2 inhibitors on ultrafiltration in patients with peritoneal dialysis: a protocol for a randomized, double-blind, placebo-controlled, crossover trial (EMPOWERED).
Doi Y; Shinzawa M; Arisato T; Oka H; Matsumoto A; Kitamura H; Nakazono Y; Nishiya Y; Ueda Y; Kamimura T; Hayashi T; Yoshihara F; Isaka Y
Clin Exp Nephrol; 2024 Jul; 28(7):629-635. PubMed ID: 38402502
[TBL] [Abstract][Full Text] [Related]
18. The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial.
Sargeant JA; King JA; Yates T; Redman EL; Bodicoat DH; Chatterjee S; Edwardson CL; Gray LJ; Poulin B; Waheed G; Waller HL; Webb DR; Willis SA; Wilding JPH; Khunti K; Stensel DJ; Davies MJ
Diabetes Obes Metab; 2022 Aug; 24(8):1509-1521. PubMed ID: 35441435
[TBL] [Abstract][Full Text] [Related]
19. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.
Shimizu W; Kubota Y; Hoshika Y; Mozawa K; Tara S; Tokita Y; Yodogawa K; Iwasaki YK; Yamamoto T; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Ishikawa M; Maruyama M; Ogano M; Tanabe J;
Cardiovasc Diabetol; 2020 Sep; 19(1):148. PubMed ID: 32977831
[TBL] [Abstract][Full Text] [Related]
20. Nutrient re-routing and altered gut-islet cell crosstalk may explain early relief of severe postprandial hypoglycaemia after reversal of Roux-en-Y gastric bypass.
Svane MS; Toft-Nielsen MB; Kristiansen VB; Hartmann B; Holst JJ; Madsbad S; Bojsen-Møller KN
Diabet Med; 2017 Dec; 34(12):1783-1787. PubMed ID: 28782840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
